Quanterix Corp
NASDAQ:QTRX

Watchlist Manager
Quanterix Corp Logo
Quanterix Corp
NASDAQ:QTRX
Watchlist
Price: 10.52 USD -1.22% Market Closed
Market Cap: 403.8m USD
Have any thoughts about
Quanterix Corp?
Write Note

Quanterix Corp
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Quanterix Corp
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Quanterix Corp
NASDAQ:QTRX
Net Income (Common)
-$39.7m
CAGR 3-Years
-10%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.1B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.9B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
9%
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
42%
CAGR 10-Years
15%
No Stocks Found

Quanterix Corp
Glance View

Market Cap
403.9m USD
Industry
Life Sciences Tools & Services

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 460 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers at extremely low concentrations in blood, serum and other fluids. Its products include HD-X Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, and 2470 Arrayer. The company also supplies NF-Light antibodies and ELISA kits, which offer solutions for the detection of neurofilament light (Nf-L) for the development of therapeutics and diagnostics for neurodegenerative conditions. Its portfolio of available kits spans multiple therapeutic areas, including cardiology, infectious disease, inflammation, neurology, and oncology. The company provides services through its Simoa Accelerator Laboratory.

QTRX Intrinsic Value
16.45 USD
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Quanterix Corp's Net Income (Common)?
Net Income (Common)
-39.7m USD

Based on the financial report for Jun 30, 2024, Quanterix Corp's Net Income (Common) amounts to -39.7m USD.

What is Quanterix Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-1%

Over the last year, the Net Income (Common) growth was 40%. The average annual Net Income (Common) growth rates for Quanterix Corp have been -10% over the past three years , -1% over the past five years .

Back to Top